Selected data models

You must log in to select data models for download or further analysis.

6 Search results.
Relevance Rating New first Old first

Investigational Product – IV Dosing Day 1 Post- Infection Mepolizumab HES NCT00086658 - Investigational Product – IV Dosing Day 1 Post- Infection

- 6/11/17 - 1 form, 1 itemgroup, 6 items, 1 language
Itemgroup: Investigational Product Dose Intravenous
Study part: Investigational Product – IV Dosing Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pharmacokinetics- Blood Day 1 Post- Infection Mepolizumab HES NCT00086658 - Pharmacokinetics- Blood Day 1 Post- Infection

- 6/11/17 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: Pharmacokinetics Blood
Study part: Pharmacokinetics- Blood Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Central Laboratory –Blood Day 1 Post- Infection Mepolizumab HES NCT00086658 - Central Laboratory –Blood Day 1 Post- Infection

- 6/11/17 - 1 form, 1 itemgroup, 2 items, 1 language
Itemgroup: Central laboratory
Study part: Central Laboratory –Blood Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Randomisation Number Day 1 Post- Infection Mepolizumab HES NCT00086658 - Randomisation Number Day 1 Post- Infection

- 6/11/17 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: Randomisation Number
Study part: Randomisation Number Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Concomitant Medications Day 1 Post- Infection Mepolizumab HES NCT00086658 - Concomitant Medications Day 1 Post- Infection

- 6/11/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Concomitant Medications
Study part: Concomitant Medications Day 1 Post- Infection .A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Adverse Events Day 1 Post- Infection Mepolizumab HES NCT00086658 - Adverse Events Day 1 Post- Infection

- 6/11/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Adverse Events
Study part: Adverse Events Day 1 Post- Infection. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial